These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1171 related items for PubMed ID: 19055701

  • 1. Residual viraemia in HIV-1-infected patients with plasma viral load <or=20 copies/ml is associated with increased blood levels of soluble immune activation markers.
    Ostrowski SR, Katzenstein TL, Pedersen BK, Gerstoft J, Ullum H.
    Scand J Immunol; 2008 Dec; 68(6):652-60. PubMed ID: 19055701
    [Abstract] [Full Text] [Related]

  • 2. Plasma levels of viro-immunological markers in HIV-infected and non-infected Ethiopians: correlation with cell surface activation markers.
    Messele T, Brouwer M, Girma M, Fontanet AL, Miedema F, Hamann D, Rinke de Wit TF.
    Clin Immunol; 2001 Feb; 98(2):212-9. PubMed ID: 11161977
    [Abstract] [Full Text] [Related]

  • 3. [Evaluation for two-year highly active antiretroviral therapy in Chinese HIV-1 infection patients].
    Li H, Zheng YH, Shen Z, Liu M, Liu C, He Y, Chen J, Ou QY, Huang ZL.
    Zhonghua Yi Xue Za Zhi; 2007 Nov 13; 87(42):2973-6. PubMed ID: 18261327
    [Abstract] [Full Text] [Related]

  • 4. Detection and quantification of proviral HIV-1 184 M/V in circulating CD4(+) T cells of patients on HAART with a viremia less than 1,000 copies/ml.
    Mohey R, Jørgensen LB, Møller BK, Black FT, Kjems J, Obel N.
    J Clin Virol; 2005 Dec 13; 34(4):257-67. PubMed ID: 16286049
    [Abstract] [Full Text] [Related]

  • 5. Role of hepatitis C virus (HCV) viremia and HCV genotype in the immune recovery from highly active antiretroviral therapy in a cohort of antiretroviral-naive HIV-infected individuals.
    Antonucci G, Girardi E, Cozzi-Lepri A, Capobianchi MR, De Luca A, Puoti M, Petrelli E, Carnevale G, Rizzardini G, Grossi PA, Viganò P, Moioli MC, Carletti F, Solmone M, Ippolito G, Monforte AD, HepaI.Co.N.A. Study Group, Italian Cohort Naive for Antiretrovirals Study Group.
    Clin Infect Dis; 2005 Jun 15; 40(12):e101-9. PubMed ID: 15909251
    [Abstract] [Full Text] [Related]

  • 6. HIV-1 viral replication below 50 copies/ml in patients on antiretroviral therapy is not associated with CD8+ T-cell activation.
    Steel A, Cox AE, Shamji MH, John L, Nelson M, Henderson DC, Gotch FM, Gazzard BG, Kelleher P.
    Antivir Ther; 2007 Jun 15; 12(6):971-5. PubMed ID: 17926652
    [Abstract] [Full Text] [Related]

  • 7. Mechanisms involved in the low-level regeneration of CD4+ cells in HIV-1-infected patients receiving highly active antiretroviral therapy who have prolonged undetectable plasma viral loads.
    Benveniste O, Flahault A, Rollot F, Elbim C, Estaquier J, Pédron B, Duval X, Dereuddre-Bosquet N, Clayette P, Sterkers G, Simon A, Ameisen JC, Leport C.
    J Infect Dis; 2005 May 15; 191(10):1670-9. PubMed ID: 15838794
    [Abstract] [Full Text] [Related]

  • 8. Long-term suppression of plasma viremia with highly active antiretroviral therapy despite virus evolution and very limited selection of drug-resistant genotypes.
    Pariente N, Pernas M, de la Rosa R, Gómez-Mariano G, Fernández G, Rubio A, López M, Benito JM, López-Galíndez C, Leal M, Domingo E, Martinez MA, Mas A.
    J Med Virol; 2004 Jul 15; 73(3):350-61. PubMed ID: 15170628
    [Abstract] [Full Text] [Related]

  • 9. Limited long-term naive CD4+ T cell reconstitution in patients experiencing viral load rebounds during HAART.
    Choremi-Papadopoulou H, Tsalimalma K, Dafni U, Dimitracopoulou A, Kordossis T.
    J Med Virol; 2004 Jun 15; 73(2):235-43. PubMed ID: 15122798
    [Abstract] [Full Text] [Related]

  • 10. Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: a cross-sectional evaluation.
    Bonora S, Nicastri E, Calcagno A, Gonzalez de Requena D, D'Ettorre G, Sarmati L, Palmisano L, Vullo V, Di Perri G, Andreoni M.
    J Med Virol; 2009 Mar 15; 81(3):400-5. PubMed ID: 19152404
    [Abstract] [Full Text] [Related]

  • 11. Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
    Hoen B, Cooper DA, Lampe FC, Perrin L, Clumeck N, Phillips AN, Goh LE, Lindback S, Sereni D, Gazzard B, Montaner J, Stellbrink HJ, Lazzarin A, Ponscarme D, Staszewski S, Mathiesen L, Smith D, Finlayson R, Weber R, Wegmann L, Janossy G, Kinloch-de Loes S, QUEST Study Group.
    Clin Infect Dis; 2007 Aug 01; 45(3):381-90. PubMed ID: 17599319
    [Abstract] [Full Text] [Related]

  • 12. Association between cellular human immunodeficiency virus DNA level and immunological parameters in patients with undetectable plasma viremia level during highly active antiretroviral therapy.
    Sarmati L, Parisi SG, Nicastri E, d'Ettorre G, Palmisano L, Andreotti M, Andreoni C, Giuliano M, Gatti F, Boldrin C, Palù G, Vullo V, Vella S, Andreoni M.
    J Clin Microbiol; 2005 Dec 01; 43(12):6183-5. PubMed ID: 16333125
    [Abstract] [Full Text] [Related]

  • 13. Altered clonogenic capability and stromal cell function characterize bone marrow of HIV-infected subjects with low CD4+ T cell counts despite viral suppression during HAART.
    Isgrò A, Leti W, De Santis W, Marziali M, Esposito A, Fimiani C, Luzi G, Pinti M, Cossarizza A, Aiuti F, Mezzaroma I.
    Clin Infect Dis; 2008 Jun 15; 46(12):1902-10. PubMed ID: 18462177
    [Abstract] [Full Text] [Related]

  • 14. Characterization of GBV-C infection in HIV-1 infected patients.
    Canducci F, Uberti Foppa C, Boeri E, Racca S, Gallotta G, Grasso MA, Calori G, Lazzarin A, Clementi M.
    J Biol Regul Homeost Agents; 2003 Jun 15; 17(2):191-4. PubMed ID: 14518722
    [Abstract] [Full Text] [Related]

  • 15. Behavior of serum human major histocompatibility complex class I antigen levels in human immunodeficiency virus-infected patients during antiretroviral therapy: correlation with clinical outcome.
    Murdaca G, Contini P, Setti M, Cagnati P, Villa R, Lantieri F, Indiveri F, Puppo F.
    Hum Immunol; 2007 Nov 15; 68(11):894-900. PubMed ID: 18082568
    [Abstract] [Full Text] [Related]

  • 16. Activation and coreceptor expression of T lymphocytes induced by highly active antiretroviral therapy in Chinese HIV/AIDS patients.
    Zhang ZN, Shang H, Jiang YJ, Liu J, Dai D, Diao YY, Geng WQ, Jin X, Wang YN.
    Chin Med J (Engl); 2006 Dec 05; 119(23):1966-71. PubMed ID: 17199940
    [Abstract] [Full Text] [Related]

  • 17. Potent antiretroviral therapy of primary human immunodeficiency virus type 1 (HIV-1) infection: partial normalization of T lymphocyte subsets and limited reduction of HIV-1 DNA despite clearance of plasma viremia.
    Zaunders JJ, Cunningham PH, Kelleher AD, Kaufmann GR, Jaramillo AB, Wright R, Smith D, Grey P, Vizzard J, Carr A, Cooper DA.
    J Infect Dis; 1999 Aug 05; 180(2):320-9. PubMed ID: 10395845
    [Abstract] [Full Text] [Related]

  • 18. CD8+ anti-human immunodeficiency virus suppressor activity (CASA) in response to antiretroviral therapy: loss of CASA is associated with loss of viremia.
    Wilkinson J, Zaunders JJ, Carr A, Cooper DA.
    J Infect Dis; 1999 Jul 05; 180(1):68-75. PubMed ID: 10353863
    [Abstract] [Full Text] [Related]

  • 19. CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study.
    Kaufmann GR, Perrin L, Pantaleo G, Opravil M, Furrer H, Telenti A, Hirschel B, Ledergerber B, Vernazza P, Bernasconi E, Rickenbach M, Egger M, Battegay M, Swiss HIV Cohort Study Group.
    Arch Intern Med; 2003 Oct 13; 163(18):2187-95. PubMed ID: 14557216
    [Abstract] [Full Text] [Related]

  • 20. Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week study.
    Llibre JM, Buzón MJ, Massanella M, Esteve A, Dahl V, Puertas MC, Domingo P, Gatell JM, Larrouse M, Gutierrez M, Palmer S, Stevenson M, Blanco J, Martinez-Picado J, Clotet B.
    Antivir Ther; 2012 Oct 13; 17(2):355-64. PubMed ID: 22290239
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 59.